Implanet reported revenue up in the third quarter of 2015.
Here are eight key notes on the company's financial report:
1. Third quarter revenue was up 42 percent in 2015 compared with the same time period in 2014.
2. The company's spine line, JAZZ, revenue doubled over the quarter — up 101 percent. The spine sales accounted for 47 percent of the total sales, compared with 24 percent of total sales in the third quarter of last year.
3. Knee and arthroscopy revenue was up 14 percent over the same period last year.
4. For the nine months end, the group sales decreased 4 percent due to the company discontinuing hip activity in the second quarter of 2014. Excluding the hip activity, revenue for the first nine months of 2015 was up 13 percent.
5. The spine revenue in the first nine months was up 76 percent, however the knee and arthroscopy revenue was down 13 percent for the same time period.
6. The United States is the largest contributor to the spine growth, up 158 percent year-to-date over the same period last year. The company has sold 771 JAZZ units in the United States and 1,951 in France; in the rest of the world, there were 1,684 units sold.
7. The company recently sold its 10,000th JAZZ implant
8. CEO Ludovic Lastennet reports interest at the recent Scoliosis Research Society and North American Spine Society annual meetings in the technology from both patients and surgeons. "We are confident that our growth will continue, driven by our financial resources and continued marketing expansion in the world's most dynamic markets, notably in the United States and Latin America," he said.